MA38782A1 - Dry powder formulation with anticholinergic, corticosteroid and beta-adrenergic for administration by inhalation - Google Patents

Dry powder formulation with anticholinergic, corticosteroid and beta-adrenergic for administration by inhalation

Info

Publication number
MA38782A1
MA38782A1 MA38782A MA38782A MA38782A1 MA 38782 A1 MA38782 A1 MA 38782A1 MA 38782 A MA38782 A MA 38782A MA 38782 A MA38782 A MA 38782A MA 38782 A1 MA38782 A1 MA 38782A1
Authority
MA
Morocco
Prior art keywords
anticholinergic
corticosteroid
inhalation
adrenergic
beta
Prior art date
Application number
MA38782A
Other languages
French (fr)
Other versions
MA38782B1 (en
Inventor
Irene Pasquali
Rossella Musa
Azita Askey-Sarvar
Francesca Schiaretti
Original Assignee
Chiesi Farma Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/EP2014/064824 external-priority patent/WO2015004243A1/en
Application filed by Chiesi Farma Spa filed Critical Chiesi Farma Spa
Publication of MA38782A1 publication Critical patent/MA38782A1/en
Publication of MA38782B1 publication Critical patent/MA38782B1/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/16Amides, e.g. hydroxamic acids
    • A61K31/165Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12Carboxylic acids; Salts or anhydrides thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/007Pulmonary tract; Aromatherapy
    • A61K9/0073Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Otolaryngology (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne des formulations de poudre sèche pour l'inhalation, comprenant une combinaison d'un anticholinergique, d'un agoniste de l'adrénorécepteur de bêta2 à action prolongée et d'un corticostéroïde, leur procédé de préparation et des utilisations thérapeutiques de ces formulations.Inhalable powder formulations for inhalation comprising a combination of an anticholinergic, a long-acting beta2 adrenoreceptor agonist and a corticosteroid, a process for their preparation and therapeutic uses of these formulations.

MA38782A 2013-07-11 2016-01-08 Dry powder formulation with anticholinergic, corticosteroid and beta-adrenergic for administration by inhalation MA38782B1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP13176114 2013-07-11
PCT/EP2014/064824 WO2015004243A1 (en) 2013-07-11 2014-07-10 Dry powder formulation comprising an anticholinergic, a corticosteroid and a beta-adrenergic for administration by inhalation

Publications (2)

Publication Number Publication Date
MA38782A1 true MA38782A1 (en) 2016-04-29
MA38782B1 MA38782B1 (en) 2016-11-30

Family

ID=48793010

Family Applications (1)

Application Number Title Priority Date Filing Date
MA38782A MA38782B1 (en) 2013-07-11 2016-01-08 Dry powder formulation with anticholinergic, corticosteroid and beta-adrenergic for administration by inhalation

Country Status (2)

Country Link
AR (1) AR096878A1 (en)
MA (1) MA38782B1 (en)

Also Published As

Publication number Publication date
AR096878A1 (en) 2016-02-03
MA38782B1 (en) 2016-11-30

Similar Documents

Publication Publication Date Title
MY176176A (en) Dry powder formulation comprising an anticholinergic, a corticosteroid and a beta-adrenergic for administration by inhalation
EA201892657A1 (en) SPYROLACTAM MODULATORS OF THE NMDA-RECEPTOR AND THEIR APPLICATION
PH12015501595A1 (en) Spiro-lactam nmda receptor modulators and uses thereof
PH12015502691A1 (en) Use of high dose pridopidine for treating huntington's disease
EA033113B1 (en) Methods of treating autoimmune, respiratory and inflammatory disorders by inhalation of roflumilast n-oxide
PH12015501598A1 (en) Spiro-lactam nmda receptor modulators and uses thereof
MA35859B1 (en) Dry powder formulation comprising a corticosteroid and a beta-adrenergic for administration by inhalation
IN2014DN10548A (en)
PH12015501600A1 (en) Spiro-lactam nmda receptor modulators and uses thereof
PH12015501601B1 (en) Spiro-lactam nmda receptor modulators and uses thereof
MA43256B1 (en) Process for preparing a dry powder formulation comprising an anticholinergic, a corticosteroid and a beta-adrenergic
PH12015501596A1 (en) Spiro-lactam nmda receptor modulators and uses thereof
MA39735A (en) Dosing of cabozantinib formulations
MD20150120A2 (en) Treatment of protein aggregation myopathic and neurodegenerative diseases by parenteral administration of trehalose
UA117154C2 (en) S1p3 antagonists
MX2017013636A (en) Tamper-resistant fixed dose combination providing fast release of two drugs from different particles.
MX2019006942A (en) Non-peptide oxytocin receptor agonists.
MX2017013633A (en) Tamper-resistant fixed dose combination providing fast release of two drugs from particles.
MA38782B1 (en) Dry powder formulation with anticholinergic, corticosteroid and beta-adrenergic for administration by inhalation
HRP20230105T1 (en) N,n-bis-2-mercaptoethyl isophthalamide for the treatment of neurodegenerative diseases
TW201613600A (en) Piperazinyl derivative reduces HFD-induced accumulation of fat in the liver, therapeutically
BR112014029577A2 (en) use of inverse ghrelin receptor agonists or antagonists for the treatment of sleep disorders
Breccia Dasatinib/vincristine
Solla Levodopa/pergolide
GR1008039B (en) Stable injectable pharmaceutical composition of vitamin d receptor agonist and process for preparation thereof